Edition:
United Kingdom

People: Sino Biopharmaceutical Ltd (1177.HK)

1177.HK on Hong Kong Stock

7.80HKD
18 Apr 2019
Change (% chg)

HK$-0.17 (-2.13%)
Prev Close
HK$7.97
Open
HK$7.91
Day's High
HK$7.91
Day's Low
HK$7.71
Volume
36,620,754
Avg. Vol
69,001,823
52-wk High
HK$13.93
52-wk Low
HK$4.53

Tse, Hsin 

Mr. Tse Hsin serves as Executive Director, Vice President of Sino Biopharmaceutical Ltd. He is mainly responsible for the acquisition and merger activities of the Group. He is also the Group’s spokesman. Mr. Tse Hsin graduated from the University of Hong Kong with a Bachelor’s Degree (Honors) in Industrial Engineering. He joined the Group in August, 1995 as an assistant to the president of the Company and served as the general manager of Xian C.P. Pharmaceutical Co., Ltd. Mr. Tse Hsin is a council member of the first council and the executive council member of the second council of Chaozhou Natives Chamber of Commerce Beijing. He is also an executive member of the Right Protection Association for the Medical Treatment Equipment Enterprises of the Shaanxi Province, the vice chairman of the fourth council of the Foreign Invested Enterprises Association of the Shaanxi Province, the executive member of the third committee of the Shaanxi Cancer Fighting Association and the vice chairman of the World Chinese Medicine and Pharmaceutical Professional Joint Committee. He was also awarded the “Outstanding Management Award for Foreign-invested Enterprises of Shaanxi Province” and “Outstanding entrepreneur who cares about his staff” by the Shaanxi Provincial Government. He was an executive director of Beijing Tide. He is currently a director of CT Tianqing, NJCTT, and Qingdao CT and the president of Chia Tai Shaoyang Orthopedic Hospital. He is an uncle of Miss Tse, Theresa Y Y, the Chairlady of the Board, and a first cousin of Mr. Tse Ping, an Executive Director and a substantial shareholder of the Company. He is also the brother of Miss Tse Wun and a first cousin of Ms. Chia Fai and Mr. Tse Hsuan, Johnny, all being senior management of the Company.

Basic Compensation

Total Annual Compensation, HKD 2,164,000
Restricted Stock Award, HKD --
Long-Term Incentive Plans, HKD --
All Other, HKD 16,000
Fiscal Year Total, HKD 2,180,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Y Y Tse

8,870,000

Ping Tse

36,727,000

Cheung Ling Cheng

11,116,000

Minggang Wang

--

Chun Ling Li

--

Hsin Tse

2,180,000
As Of  31 Dec 2017